See more : Metalliance SA (MLETA.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Mind Cure Health Inc. (MCURF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Cure Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Gillanders Arbuthnot and Company Limited (GILLANDERS.BO) Income Statement Analysis – Financial Results
- China VAST Industrial Urban Development Company Limited (6166.HK) Income Statement Analysis – Financial Results
- Karyopharm Therapeutics Inc. (KPTI) Income Statement Analysis – Financial Results
- Silence Therapeutics plc (SLN) Income Statement Analysis – Financial Results
- Shopify Inc. (SHOP.TO) Income Statement Analysis – Financial Results
Mind Cure Health Inc. (MCURF)
About Mind Cure Health Inc.
Mind Cure Health Inc., a life sciences company, develops and commercializes mental health and wellness products in North America. It focuses on the development of digital therapeutics technology and researching psychedelic compounds to rapidly scale science-backed and evidence-based mental health therapy. The company develops iSTRYM, a digital therapeutics tool and first-of-its-kind software application that optimizes the healing journey for patients and clinicians before, during, and after therapy sessions; PsyCollage, a bioinformatics platform that helps to drive research by identifying priority research programs; synthetic ibogaine to supply researchers and clinicians; and psychedelic compounds, including ibogaine for traumatic brain injuries and related conditions. Mind Cure Health Inc. was incorporated in 2020 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 48.25K | 50.36K |
| General & Administrative | 9.74M | 10.21M |
| Selling & Marketing | 262.69K | 204.55K |
| SG&A | 10.00M | 10.41M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 10.06M | 10.46M |
| Cost & Expenses | 10.06M | 10.46M |
| Interest Income | 94.41K | 33.25K |
| Interest Expense | 0.00 | 0.00 |
| Depreciation & Amortization | 9.75K | 236.56K |
| EBITDA | -5.88M | -10.73M |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -5.89M | -10.73M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.25M | 789.04K |
| Income Before Tax | -14.14M | -10.17M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 4.08M | 0.00 |
| Net Income | -14.14M | -10.17M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -0.15 | -0.18 |
| EPS Diluted | -0.15 | -0.18 |
| Weighted Avg Shares Out | 93.85M | 57.31M |
| Weighted Avg Shares Out (Dil) | 93.85M | 57.31M |
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
Mind Cure Comments on Recent Promotional Activity
Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Source: https://incomestatements.info
Category: Stock Reports